Arherosclerosis, 58 (1985) 291-294 Elsevier 291 ATH 03700 Preliminary Note Blood Lipid Profile in Healthy Subjects Treated with Ticlopidine F. Violi, C. Alessandri, L. Iuliano, A. Ghiselli, A. Perrone and F. Balsano Institute of Clinical Medrcine I, University of Rome, “ La Saprenra” , Rome (Italy) (Received 7 March, 1985) (Revised, received 27 June, 1985) (Accepted 27 June, 1985) The study was carried out in order to evaluate if Ticlopidine induces lipid metabolism changes. Twenty seven healthy subjects were studied, 14 with placebo and 13 with Ticlopidine treatment (500 mg/day), for 30 days. Total cholesterol, HDL cholesterol, triglycerides, apolipoproteins A and B were evaluated before and after treatment. No significant changes of the blood lipid parameters were observed. Key words: Lipids - Ticlopidine - Introduction Ticlopidine (T), a new antiplatelet drug, inhibits platelet function in vitro and in vivo [l]. In man, T induces a decrease of ADP and collagen-induced platelet aggregation [2], a bleeding time prolongation [3] and a lowering of beta-thrombo- globulin plasma levels [2]. The mechanism of action of T is not fully understood, although it has been suggested that it could inhibit platelet function by affecting ADP-induced platelet fibrinogen binding and plasma fibronectin [4,5]. In the long-term treatment of atherosclerosis with antiplatelet drugs, it is important to consider the possible effects of the therapy on other risk factors, such as the abnormalities in the blood lipid pattern, that often occur in patients with Correspondence to: Prof. F. Violi, Institute of Clinical Medicine I, University of Rome, Policlinico Umberto I, 00161 Rome, Italy. 0021-9150/85/$03.30 0 1985 Elsevier Scientific Publishers Ireland. Ltd.